US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Vima Therapeutics

News headline image
Vima Therapeutics to Present New Research at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
From Vima Therapeutics
Via GlobeNewswire
News headline image
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease
From Vima Therapeutics
Via GlobeNewswire
News headline image
Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
From Vima Therapeutics
Via GlobeNewswire